Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (formerly traded on Nasdaq under the symbol SCPH) generated a steady stream of company-specific news before and during its acquisition by MannKind Corporation. Public announcements and SEC filings show that scPharmaceuticals focused on cardiorenal healthcare, with news often centered on FUROSCIX, a subcutaneous furosemide injection indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
News coverage for scPharmaceuticals has included product and clinical updates, such as FDA approval of an expanded FUROSCIX indication to include chronic kidney disease and the formal launch of FUROSCIX into that market. The company also reported progress on its SCP-111 furosemide formulation and related autoinjector program, including multiple Notices of Allowance from the U.S. Patent and Trademark Office for patents covering SCP-111 and plans for supplemental NDA submissions.
Financial and corporate updates have been another major theme. scPharmaceuticals regularly issued press releases on quarterly and annual financial results, highlighting net FUROSCIX revenues, dose volumes, prescriber adoption, and expansion into integrated delivery networks. Additional news detailed participation in investor conferences, financing arrangements, and credit facilities.
A key set of news items in 2025 described MannKind’s agreement to acquire scPharmaceuticals, the tender offer terms, and the strategic rationale around cardiorenal and cardiometabolic care. Subsequent releases and a Form 8-K dated October 7, 2025 confirmed completion of the tender offer and merger, after which scPharmaceuticals became a wholly owned subsidiary of MannKind and its shares were delisted from Nasdaq. This news page therefore serves as an archive of historical announcements, from product and regulatory milestones to the transaction that ended SCPH’s life as an independent public stock.
scPharmaceuticals Inc. (Nasdaq: SCPH), a company focused on optimizing infused therapies, will have its President & CEO, John Tucker, present at the Jefferies London Healthcare Conference on November 16 at 5:35 pm GMT (12:35 pm ET). The event will be accessible via a live webcast in the Investor Relations section of their website. The company specializes in developing products to reduce healthcare costs and improve patient outcomes, particularly in heart failure and infectious diseases.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call on November 9, 2022, at 4:30 p.m. ET to discuss third-quarter financial results and provide a business update. The call will be accessible via phone or through an audio webcast. The company focuses on optimizing infused therapies to enhance patient care and reduce healthcare costs, with key programs on subcutaneous, self-administered treatments for heart failure and infectious diseases.
scPharmaceuticals Inc. announced FDA approval for FUROSCIX (furosemide injection), designed for treating congestion in adults with Class II/III chronic heart failure. The unique formulation allows for subcutaneous administration at home via the On-Body Infusor, ensuring 99.6% bioavailability and comparable diuresis to intravenous treatments. FUROSCIX will be commercially launched in Q1 2023, addressing a significant market potential of $5.9 billion in the U.S. This innovation aims to reduce hospital admissions among heart failure patients, enhancing patient care and healthcare cost efficiency.
scPharmaceuticals Inc. (SCPH) announced a $100 million secured debt facility with Oaktree Capital Management to support the U.S. launch of FUROSCIX, approved by the FDA on October 7, 2022. The financing includes an immediate $50 million upon signing definitive agreements, with another $50 million contingent on meeting specific commercial milestones. The debt facility, with a capped interest rate of 11.75%, will enable the company to repay existing debt and facilitate its commercial launch efforts.
scPharmaceuticals (Nasdaq: SCPH) announced FDA approval for FUROSCIX®, a proprietary furosemide formulation for treating congestion due to fluid overload in adult patients with chronic heart failure (NYHA Class II/III). FUROSCIX, the first FDA-approved subcutaneous loop diuretic, offers IV-equivalent diuresis, allowing at-home administration via the On-Body Infusor, targeting a significant U.S. market of $5.9 billion. The commercial launch is set for Q1 2023, aiming to enhance patient care and reduce hospital admissions for over 7 million heart failure patients.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced two poster presentations at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, highlighting the clinical benefits of FUROSCIX® (furosemide injection) in treating heart failure congestion at home. Data from a pilot study showed that patients using FUROSCIX experienced significantly greater weight reduction and improved dyspnea scores compared to those on oral diuretics. The company anticipates a robust launch for FUROSCIX following its October 8 PDUFA date, pending FDA approval.
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company specializing in optimizing infused therapies, announced that CEO John Tucker will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. His presentation will be available for on-demand viewing starting September 12 at 7:00 am ET. Attendees can also schedule virtual one-on-one meetings with Tucker during the conference. The replay will be accessible in the Investor Relations section of scPharmaceuticals' website.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA acceptance of their FUROSCIX NDA, scheduled for review on October 8, 2022. The company is preparing for a Q4 2022 launch, pending approval. Financially, scPharmaceuticals ended Q2 2022 with $56 million in cash, down from $75.5 million at year-end 2021. They reported a net loss of $9.7 million for Q2 2022, up from $7.1 million in Q2 2021. Research and development expenses rose to $5.1 million, and general and administrative expenses increased to $4.3 million. The company projects a net loss between $43 million and $48 million for 2022.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a panel discussion on heart failure therapeutics on July 14, 2022, at 10:00 a.m. ET. The event is hosted by Maxim Group LLC and will be available live on M-Vest. The company is dedicated to developing products that enhance infused therapy delivery, improve patient care, and lower healthcare costs. Their focus includes self-administered IV-strength treatments for heart failure and infectious diseases.
scPharmaceuticals Inc. (SCPH) announced positive results from its AT HOME-HF Pilot study, evaluating FUROSCIX for chronic heart failure patients. The study showed a 37% reduction in heart failure hospitalizations and improvements in symptoms and quality of life. Subjects using FUROSCIX experienced greater weight loss and higher Kansas City Cardiomyopathy Questionnaire scores. Although there were some mild adverse events, the tolerability profile was deemed acceptable. With a PDUFA date set for October 8, 2022, the company aims for a Q4 2022 commercial launch of FUROSCIX, pending regulatory approval.